eAppendix. Additional Information on Study Methods
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Reyes Gil M, Barouqa M, Szymanski J, Gonzalez-Lugo JD, Rahman S, Billett HH. Assessment of Lupus Anticoagulant Positivity in Patients With Coronavirus Disease 2019 (COVID-19). JAMA Netw Open. 2020;3(8):e2017539. doi:10.1001/jamanetworkopen.2020.17539
Antiphospholipid syndrome (APS) is an autoimmune disease that manifests as arterial, venous, or microcirculatory thromboses as well as obstetric complications.1 The diagnosis of APS requires the presence of IgG or IgM anti-β2-glycoprotein-1 or anticardiolipin antibodies by enzyme-linked immunosorbent assay or lupus anticoagulant (LA) assays that must persist for more than 12 weeks. Coagulopathy in patients with coronavirus disease 2019 (COVID-19) is a common complication that jeopardizes the clinical course and is associated with poorer outcomes.2,3 This COVID-19 coagulopathy presents mainly as a prothrombotic state, and there is evidence that anticoagulation may reduce mortality rates.4 The partial thromboplastin time (PTT) has been found to be prolonged in many patients with COVID-19 and may indicate the presence of LA.5 Most patients with COVID-19 have elevated levels of C-reactive protein (CRP), and CRP is known to interfere with LA PTT-based tests, such as the hexagonal phase phospholipid neutralization assay STACLOT-LA.6
This cohort study was approved by the Albert Einstein College of Medicine institutional review board. We performed a retrospective study to understand the demographic, laboratory, and clinical characteristics of LA-positive patients with COVID-19 (see study design and methods in the eAppendix in the Supplement). LA positivity was determined by the dilute Russell viper venom time (DRVVT). Most samples were also screened for STACLOT-LA and LA serological testing. Statistical methods to study association of LA with outcomes included Fisher exact tests for categorical values, 2-sample t-tests for parametric values, Kruskal-Wallis tests for nonparametric values, and logistic regression of DRVVT adjusted by CRP. The threshold for statistical significance was set at 2-tailed P < .05. R statistical software version 3.6.2 (R Project for Statistical Computing) was used for analysis.
One hundred eighty-seven patients had LA testing ordered from March 1 to April 30, 2020, at Montefiore Medical Center, a large tertiary center in the Bronx, New York. Of those, 119 were not tested or tested negative by COVID reverse transcriptase–polymerase chain reaction. The LA-positive rate by DRVVT in patients who tested negative for COVID-19 was 22% (27 of 119). In contrast, the LA-positive rate in patients who tested positive for COVID-19 was 44% (30 of 68) (P = .002). Of the 30 COVID-19–positive patients who had a positive LA by DRVVT, 17 (59%) were also positive by hexagonal phospholipid neutralization STACLOT-LA test (Table 1). Eleven (16%) were positive only for STACLOT-LA and those had significantly higher CRP levels. Mean prothrombin time and PTT were more prolonged in LA-positive compared with LA-negative patients (Table 1). Importantly, of the 30 patients who were LA positive, 19 had documented thrombosis (arterial and venous), an event rate of 63%, as compared with a rate for LA-negative patients of 34% (P = .03). No statistically significant difference was found by gender, race, ethnicity, ventilation, mortality, and anticoagulation at the time of thrombosis between patients who tested LA positive vs negative (Table 1). Although the mean CRP level was higher in patients testing positive for LA by DRVVT (14.4 vs 7.5 mg/dL; P < .01), patients with thromboses did not have significantly higher CRP levels than those with no thromboses (Table 2). After adjusting for CRP, LA was found to be independently associated with thrombosis (odds ratio, 4.39; 95% CI, 1.45-14.57; P = .01). Although D-dimer (dimerized plasmin fragment D) on admission was not different between patients with and without LA, initial D-dimer was significantly higher in patients who developed a thrombotic event compared with patients without clots (9.14 vs 4.98 μg/mL; P = .04) (Table 2). Only 1 patient among those positive for LA by DRVVT had IgM antibodies against β2-glycoprotein-1 and cardiolipin. The rest were negative for IgM and IgG antibodies against both β2-glycoprotein-1 and cardiolipin.
This cohort study found an increased incidence of LA positivity in patients with COVID-19 after adjusting for CRP levels. In addition, LA was associated with incidence of thrombosis in patients with COVID-19. Limitations of this retrospective study include a small sample size and inability to control time of LA testing from admission to outcome (mortality and thrombosis). LA-positive individuals have a marked risk of arterial and venous thrombosis, and therapeutic anticoagulation should be considered in these patients.
Accepted for Publication: July 4, 2020.
Published: August 12, 2020. doi:10.1001/jamanetworkopen.2020.17539
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Reyes Gil M et al. JAMA Network Open.
Corresponding Author: Morayma Reyes Gil, MD, PhD, Montefiore Medical Center, Department of Pathology, Albert Einstein School of Medicine, 111 E 210th St, Foreman 8, The Bronx, NY 10467 (email@example.com).
Author Contributions: Drs Gil and Barouqa had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Reyes Gil, Barouqa, Rahman, Billett.
Acquisition, analysis, or interpretation of data: Reyes Gil, Barouqa, Szymanski, Gonzalez-Lugo, Rahman.
Drafting of the manuscript: Reyes Gil, Barouqa, Gonzalez-Lugo, Rahman.
Critical revision of the manuscript for important intellectual content: Reyes Gil, Szymanski, Gonzalez-Lugo, Rahman, Billett.
Statistical analysis: Reyes Gil, Barouqa.
Obtained funding: Reyes Gil.
Administrative, technical, or material support: Reyes Gil, Barouqa, Szymanski, Gonzalez-Lugo.
Supervision: Reyes Gil, Billett.
Conflict of Interest Disclosures: None reported.
Additional Contributions: We acknowledge the coagulation lab manager, Julissa Pena, and lab technologists Mayra Almonte, Leli Soriano, and Geovanna Cruz for their dedication handling and processing clinical specimens during the COVID-19 crisis. We thank Michael B. Prystowsky, MD, PhD (chair of Department of Pathology/Montefiore Medical Center, The University Hospital of Albert Einstein College of Medicine) for providing invaluable support and resources to all laboratory personnel during the COVID-19 crisis.
Create a personal account or sign in to: